The progression of cancer involves a critical step in which malignant cells escape from
control by the immune system. Antineoplastic agents are particularly efficient when they …

Mammalian cells responding to specific perturbations of homeostasis can undergo a
regulated variant of cell death that elicits adaptive immune responses. As immunogenic cell …

Immunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell
death that activates, rather than suppresses, innate and adaptive immune responses. Such …

Background The plasma concentrations of acyl coenzyme A binding protein (ACBP, also
known as diazepam-binding inhibitor, DBI, or 'endozepine') increase with age and obesity …

The search for immunostimulatory drugs applicable to cancer immunotherapy may profit
from target‐agnostic methods in which agents are screened for their functional impact on …

Simple Summary Chemoimmunotherapy is an emerging treatment option for cancer that
combines traditional chemotherapy with immunotherapy. This approach aims to increase the …

While immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the
clinical management of various malignancies, a large fraction of patients are refractory to …

Cisplatin and oxaliplatin cause the secretion of high mobility group box 1 (HMGB1) protein
from cancer cells, which is necessary for initiation of immunogenic cell death (ICD) …

Hepatocellular carcinoma (HCC) is one of the most common malignancies and the third
leading cause of cancer-related deaths globally. Hepatic arterial infusion chemotherapy …

Cisplatin is a first-line clinical agent used for treating solid tumors. Cisplatin damages the
DNA of tumor cells and induces the production of high levels of reactive oxygen species to …